Role of Bambuterol in the Management of Bronchial Asthma

Background: Asthma is a long-term inflammatory disorder of the airways characterized by wheezing, dyspnea, and cough. For the last few decades, inhalational devices have been used in the management of the disease, but compliance remains the problem. Higher doses of oral medications used with promine...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of respiratory care 2019-01, Vol.8 (1), p.27-30
Main Authors: Singh, Gurumit, Kesar, Sonal, Sambyal, Ambika, Grover, Sunil
Format: Article
Language:English
Subjects:
Asthma
Bambuterol
Health aspects
pulmonary function tests
Respiratory tract diseases
symptom score
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Asthma is a long-term inflammatory disorder of the airways characterized by wheezing, dyspnea, and cough. For the last few decades, inhalational devices have been used in the management of the disease, but compliance remains the problem. Higher doses of oral medications used with prominent side effects precluded the use of oral beta-agonist bronchodilators, and the search for an ideal beta-adrenergic bronchodilator continues. This study was conducted for evaluation of the role of oral bambuterol in the management of bronchial asthma. Aims and Objectives: Our study aimed to evaluate the potency and effectiveness of oral bambuterol in the management of the disease in fifty patients followed up over 2 weeks with objective assessment of symptom scores and changes in the frequency of rescue bronchodilator after 2 weeks of treatment. Side effects, if any, were documented for all patients. Methods: The study was conducted on fifty patients with chronic bronchial asthma. They were given 10 mg of bambuterol once daily orally for 14 days. Pulmonary function tests were performed at days 1, 7, and 14. Forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), and peak expiratory flow rate (PEFR) were measured. Patients were assessed for symptom score and side effects at days 1, 7, and 14. Results: After completion of the study, significant improvement in the symptom score, FVC, FEV1, and PEFR was obtained with minimal side effects. Conclusion: Bambuterol 10 mg oral tablet once a day provides significant improvement in pulmonary function tests and effectively reduces asthmatic symptoms with minimal side effects.
ISSN:2277-9019
2321-4899
DOI:10.4103/ijrc.ijrc_16_18